Ratings FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.04 ^USD	+1.96%		-9.57%	+17.34%

Apr. 24	FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	CI
Apr. 15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Most analysts recommend that the stock should be sold or reduced.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FIBROGEN, INC.	+17.34%	103M	B-
IQVIA HOLDINGS INC.	+1.51%	42.75B	B
LONZA GROUP AG	+49.22%	41.61B	A
MODERNA, INC.	+8.57%	41.34B	B-
CELLTRION, INC.	-12.36%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B	B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+6.35%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes